GSK and Wave Life Sciences Collaborate on Oligonucleotide Therapeutics
GSK plc and Wave Life Sciences Ltd., a clinical-stage genetic drugs company, have entered into a strategic collaboration to advance oligonucleotide therapeutics, including the preclinical RNA editing program targeting alpha-1 antitrypsin deficiency (AATD), WVE-006. The four-year discovery collaboration combines GSK’s knowledge of human genetics, as well as its global development and commercial capabilities, with Wave’s …
GSK and Wave Life Sciences Collaborate on Oligonucleotide Therapeutics Read More »